Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.

Net Loss: The net loss attributable to Serina for the year ended December 31, 2024 was $11.1 million, or $ (1.51) per basic and diluted share, compared to net income of $5.3 million, or $2.36 per ...

An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, according to a poster presented here. This molecular characterization may ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

EVM14 is the first messenger RNA (mRNA) therapeutic vaccine developed internally by the company to gain this approval. Its ...

Represents first project to enter the ECO Synthesis™ Innovation LabCore enzymes for ECO Synthesis™ technology have transitioned from research ...

A new national programme that aims to position Singapore at the forefront of advancements in RNA science and applications was officially launched ...

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform TM provides ...

In the microscopic world of bacteria, gene transfer is a powerful mechanism that can alter cellular function, drive antibiotic resistance and even shape entire ecosystems. Now an interdisciplinary ...